Skip to Content

Bevacizumab Pregnancy and Breastfeeding Warnings

Bevacizumab is also known as: Avastin, Mvasi

Bevacizumab Pregnancy Warnings

Animal studies revealed evidence of fetotoxicity and teratogenicity. Teratogenic effects included: reduced or irregular ossification in the skull, jaw, spine, ribs, tibia, and bones of the paws; fontanel, rib and hindlimb deformities; corneal opacity; and absent hindlimb phalanges. There are no controlled data in human pregnancy. AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

UK: Contraindicated AU, US: This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. AU TGA pregnancy category: D US FDA pregnancy category: Not assigned. Risk Summary: This drug can cause fetal harm based on animal studies and its mechanism of action. Fetal malformations have been reported; however, these reports are insufficient to determine drug associated risks. In animal reproduction studies, IV administration to pregnant animals every 3 days during organogenesis at doses approximately 1 to 10 times the clinical dose of 10 mg/kg produced fetal resorptions, decreased maternal and fetal weight gain and multiple congenital malformations including corneal opacities and abnormal ossification of the skull and skeleton including limb and phalangeal defects. Also, animal models link angiogenesis and VEGF and VEGF Receptor 2 (VEGFR2) to critical aspects of female reproduction, embryofetal development, and postnatal development. Comments: -Women of childbearing potential should be encouraged to use adequate methods of contraception during and for at least 6 months after therapy. -Advise pregnant women of the potential risk to a fetus. -This drug could impair female fertility. Fertility preservation methods should be discussed with women of child bearing potential before initiation of treatment.

See references

Bevacizumab Breastfeeding Warnings

Use is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: -Women should discontinue breastfeeding during and for at least 6 months after therapy. -Human IgG1 is secreted into human milk. The potential for absorption and harm to the infant is unknown.

No information is available on the IV use of this drug during breastfeeding. Because it is a large protein molecule, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant GI tract. The manufacturer recommends that breastfeeding be discontinued during therapy.

See references

References for pregnancy information

  1. "Product Information. Avastin (bevacizumab)." Genentech, South San Francisco, CA.
  2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL:" ([2006]):
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL:" ([2006]):
  3. "Product Information. Avastin (bevacizumab)." Genentech, South San Francisco, CA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.